Hence, the cMET inhibitor foretinib was investigated for the treatment of this subgroup of medulloblastoma, and it showed acceptable penetration of the blood–brain barrier and significant suppression of the proliferation and migration of SHH-activated medulloblastomas in xenograft mouse models [90]. This evidence concerns the gene SHH and medulloblastoma.